Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Published in Oncology

Journal Scan / Research · April 21, 2024

Prognostic Value of HER2DX in Patients With Early-Stage HER2-Positive Breast Cancer

ESMO Open

 

 Save  Recommend
 Share

Additional Info

ESMO Open
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)
ESMO Open 2024 Mar 01;9(3)102388, G Villacampa, T Pascual, F Brasó-Maristany, L Paré, O Martínez-Sáez, J Cortés, E Ciruelos, M Martin, P Conte, LA Carey, A Fernandez, N Harbeck, M Marín-Aguilera, A Vivancos, G Curigliano, P Villagrasa, JS Parker, CM Perou, A Prat, SM Tolaney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated